Form 4: Esperion Therapeutics Executive Eric Warren Sells Shares to Cover Tax Obligations

Chief Commercial Officer of Esperion Therapeutics, Eric Warren, sold 2,540 shares of common stock on June 18, 2024, to satisfy tax obligations related to vested restricted stock units.

Summary

• On June 18, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 2,540 shares of the company's common stock.
• The shares were sold at a price of $2.856 per share.
• The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
• Following the sale, Warren directly owns 165,586 shares of Esperion Therapeutics.
• The filing also includes a Limited Power of Attorney granted by Eric Warren to Sheldon L. Koenig and Richard B. Bartram, effective February 28, 2022, allowing them to act on his behalf for SEC filings related to Esperion Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's performance or future prospects.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning or tax obligations. The sale itself doesn't necessarily indicate a negative outlook on the company, but it's something investors often monitor.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small number of shares involved.

Key Dates